Introduction
============

Colorectal cancer is the third most common cancer in Korea and worldwide, with a total of 73,759 cancer deaths occurring in Korea during 2012, accounting for 26.7% of all deaths \[[@b1-crt-2016-128],[@b2-crt-2016-128]\]. According to the seventh edition of the American Joint Committee on Cancer, the 5-year relative survival rate for stage II and III rectal cancer is 61.6%-78.7% and 31.2%-85.1%, respectively \[[@b3-crt-2016-128]\].

Type II diabetes mellitus (DM) increases the risk of numerous cancer types, including colorectal cancer \[[@b4-crt-2016-128],[@b5-crt-2016-128]\]. A large cohort study showed that the mortality rate of patients with diabetes is higher than that of patients without diabetes in several cancers \[[@b6-crt-2016-128]\]. In addition, type 2 DM is associated with a 40%-60% increased risk of colorectal cancer \[[@b7-crt-2016-128]\]. Metformin is the most common antidiabetic drug \[[@b8-crt-2016-128]\]. Recently, in addition to its antidiabetic effect, it has been shown to reduce the incidence of malignancy and cancer-related mortality \[[@b9-crt-2016-128],[@b10-crt-2016-128]\]. Several meta-analyses and epidemiologic studies evaluated the effects of metformin on the of incidence cancer, and suggested that metformin is associated with a 20%-30% reduction in carcinogenesis including breast cancers and colorectal cancers \[[@b11-crt-2016-128],[@b12-crt-2016-128]\]. Inhibition of the mammalian target of the rapamycin pathway has been considered as a mechanism to explain the antitumor effects of metformin \[[@b13-crt-2016-128]\]. In addition, decreasing the insulin levels in the blood by increasing the insulin sensitivity in patients with diabetes has been considered as a mechanism to explain the antitumor effect of metformin because insulin is considered a tumor growth factor. Although the molecular mechanism describing the antitumor effects of metformin has been elucidated for several years, the effects of metformin in human cancer is an ongoing area of research.

Many studies have shown that in colorectal cancer, metformin is associated with a tumor preventive effect as well as an anticancer effect, reducing mortality \[[@b14-crt-2016-128],[@b15-crt-2016-128]\]. On the other hand, a few clinical studies reported conflicting results when describing the effects of metformin in colorectal cancer \[[@b16-crt-2016-128]\]. In the present study, it was hypothesized that the use of metformin might have survival benefits when a homogenous cancer cohort group is analyzed to minimize any selection bias. Although colon and rectal cancer have many similar clinical features, each cancer is treated using different protocols that combine surgery, radiation therapy, and chemotherapy. For rectal cancer, with the exception of early stage cases, the standard treatment is a total mesorectal excision after preoperative chemoradiotherapy \[[@b17-crt-2016-128]\]. Metformin is associated with a higher pathologic complete response as well as improved survival in patients with rectal cancer receiving preoperative radiotherapy \[[@b18-crt-2016-128]\]. In contrast, the standard method for colon cancer treatment includes a resection followed by chemotherapy \[[@b19-crt-2016-128]\]. A study using the Surveillance, Epidemiology, and End Results (SEER) database reported differences in survival between colon and rectal cancer \[[@b20-crt-2016-128]\]. Therefore, a study of the effects of metformin on the clinical outcomes in the present study cohort focused on patients with pre-existing DM and nonmetastatic rectal cancer treated with a curative resection.

Materials and Methods
=====================

1. Data source
--------------

The data were initially provided by the Korea Center Cancer Registry (KCCR) and subsequently linked to the national claims data from the National Health Insurance Service (NHIS) of the Republic of Korea, and death registration data from the Korea National Statistical Office, using the personal identification numbers for this study under the consent of the KCCR.

The KCCR data covers cancer cases nationwide from Korea with the inclusion of the date and site of the patients' primary cancer diagnosis \[[@b1-crt-2016-128]\]. The NHIS covers 100% of the Korean population, and has comprehensive data sets of the diagnoses, treatments, procedures, surgical history, and prescription records for all insured patients. In addition, the insured population, and their dependents are all required to have periodic general health examinations.

As this study was based routinely on collected administrative data, participant consent was not specifically obtained. This study was approved by the Institutional Review Board of National Evidence-based Healthcare Collaborating Agency (NECA IRB 14-004).

2. Study subjects
-----------------

A cohort of patients with newly diagnosed rectal cancer was identified from the KCCR between 2005 and 2011 (International Classification of Diseases, 10th revision, C20). Individuals aged 18 to 90 years were eligible if they had undergone surgery for rectal cancer with the NHIS. The participants were excluded if they did not undergo surgery for rectal cancer, as well as other criteria including cases of nonadenocarcinoma, SEER stage 7 (distant site\[s\]/node\[s\] involved), familial adenomatous polyposis, ulcerative colitis or Crohn disease, synchronous metastasis, death due to complications (death during hospital stay or death due to operative complication), or insulin prescriptions (in the outpatient clinic). [Fig. 1](#f1-crt-2016-128){ref-type="fig"} presents the inclusion criteria.

3. Exposure and follow-up
-------------------------

Drug exposure was categorized into metformin or nonmetformin, including sulfonylurea, thiazolidinedione, dipeptidyl peptidase 4 inhibitors, or other oral antidiabetic drugs. Drug exposure was defined as receiving oral hypoglycemic agents (OHA) for at least 90 days during a period 6 months before the initial diagnosis of rectal cancer to the last follow-up. The medication possession ratio (MPR) was defined as the total number of days the target medication had been prescribed divided by the total number of days between the prescriptions. An MPR greater than 80% was considered as acceptable adherence. The patient cohort entry dates were the dates when each patient underwent rectal cancer surgery, and the exit date (censoring date) was the earliest date among the date of death, date recording a clinical event, 5 years after cohort entry, or end of the study period (December 31, 2013).

4. End point
------------

The primary outcome assessed was the overall survival. The rectal cancer-specific survival data was obtained from the National Population Registry of the Korea National Statistical Office until December 31, 2013, using the unique personal identification numbers.

5. Covariates
-------------

Information available from the KCCR included data on the patients' cancer diagnosis and date of diagnosis. All other demographic and clinical information was obtained from the claims data or health examination data provided by the NHIS. The cancer-related treatment data, including surgery, radiotherapy, or chemotherapy, as well as the DM-related medications were determined from the NHIS data. Comorbidities occurring from 1 year prior to rectal cancer surgery until the date of surgery were determined from the NHIS claims data.

6. Statistical analysis
-----------------------

The main analysis compared the baseline characteristics and the use of OHA in patients with and without metformin treatment. The rates of overall and rectal cancer-specific survival during the follow-up period among the patients with and without metformin treatment were compared further using the cumulative probability curves derived from Kaplan-Meier estimates. The same analysis was then used to compare the groups based on their MPR. After the unadjusted analyses were initially performed, this study conducted adjusted analyses, including the potential confounders of age, sex, Charlson's comorbidity index \[[@b21-crt-2016-128]\], SEER stage and adjuvant chemotherapy, anticancer therapy (radiotherapy, chemotherapy) before surgery, and anticancer therapy after surgery. All analyses were performed using SAS ver. 9.3 (SAS Institute Inc., Cary, NC).

Results
=======

1. Characteristics of the study population
------------------------------------------

Among 58,124 patients with rectal cancer (C20), who were diagnosed between January 1, 2005, and December 31, 2011, 26,410 underwent surgery and met none of the exclusion criteria. Of those patients, 4,503 were prescribed OHAs and were classified as diabetic, with 3,694 receiving metformin for at least 90 days ([Fig. 1](#f1-crt-2016-128){ref-type="fig"}). The median age of the metformin group was 65 years and that of the nonmetformin group was 67 years. The use of adjuvant chemotherapy was higher in the metformin group than in the nonmetformin group (30.4% vs. 26.7%) ([Table 1](#t1-crt-2016-128){ref-type="table"}).

2. Clinical outcome
-------------------

Among the patients with diabetes during the follow-up period, the overall survival and rectal cancer-specific survival was significantly higher in the metformin group than in the nonmetformin group ([Fig. 2](#f2-crt-2016-128){ref-type="fig"}). In unadjusted analyses, the metformin group showed a significantly higher overall survival (hazard ratio \[HR\], 0.596; 95% confidence interval \[CI\], 0.506 to 0.702) and rectal cancer-specific survival (HR, 0.621; 95% CI, 0.507 to 0.760) than the nonmetformin group. After multivariable analysis adjusting for the clinical covariates, the metformin group still had a significantly lower risk of events than the nonmetformin group ([Table 2](#t2-crt-2016-128){ref-type="table"}).

In the metformin group, the adjusted overall survival (HR, 0.631; 95% CI, 0.527 to 0.755) and rectal cancer-specific survival (HR, 0.598; 95% CI, 0.479 to 0.746) in patients with an MPR of 80% or greater, was significantly higher than in the patients with an MPR of less than 80% ([Table 3](#t3-crt-2016-128){ref-type="table"}, [Fig. 3](#f3-crt-2016-128){ref-type="fig"}).

Discussion
==========

Several studies have shown that DM increases the mortality of patients with colorectal cancer. Two population-based studies reported that DM is associated with reduced survival in patients with colorectal cancer \[[@b22-crt-2016-128],[@b23-crt-2016-128]\]. Three meta-analyses reported that patients with diabetes have an increased incidence of mortality from colorectal cancer \[[@b24-crt-2016-128]-[@b26-crt-2016-128]\]. In addition, Caudle et al. \[[@b27-crt-2016-128]\] compared the neoadjuvant chemoradiotherapy responses in diabetic and nondiabetic patients with rectal cancer and reported that the complete pathologic response rate was significantly higher in patients without diabetes. In contrast, a case-control study showed no significant difference in survival between patients with colorectal cancer who had well-controlled diabetic diabetes (hemoglobin A1c \< 7.5%) or who did not have diabetes \[[@b7-crt-2016-128]\].

Several studies have provided evidence describing a survival relationship between metformin use and colorectal cancer. A single institution study in Korea reported that metformin reduced the overall mortality and colorectal cancer specific mortality in diabetic patients with colorectal cancer \[[@b15-crt-2016-128]\]. In addition, metformin was reported to have survival benefits compared to other anti-diabetic agents in diabetic patients with colorectal cancer \[[@b28-crt-2016-128]\]. One meta-analysis showed that patients with colorectal cancer taking metformin had a 34% improvement in the overall survival compared to nonmetformin users \[[@b29-crt-2016-128]\]. The only data examining the benefits of metformin focusing on rectal cancer was provided by Skinner et al. \[[@b18-crt-2016-128]\]. Through a single institute cohort study, the improvement in the pathological complete response rate as well as the outcomes in patients with locally advanced rectal cancer was shown. On the other hand, other studies did not show consistent results describing the beneficial effect of metformin \[[@b16-crt-2016-128]\]. An Irish study, which compared 207 metformin receiving and 108 nonmetformin receiving patients with stage I-III colorectal cancer and diabetes, reported that the metformin group did not demonstrate a significant difference in survival compared to the nonmetformin group \[[@b30-crt-2016-128]\].

This study was based on a nationwide population database, which included a large number of patients compared to single institute cohorts. In addition, the analyzed patients included only those with nonmetastatic rectal cancer treated by a curative resection, which is considered a relatively homogeneous population with a similar prognosis.

This study has several limitations. First, the patient adherence in taking metformin cannot be confirmed exactly because only the claim data was used. Second, this study could not provide information regarding the appropriate dose of metformin required to observe any anti-tumor effects. The MPR was analyzed for metformin and showed that a higher MPR was associated with improved survival. On the other hand, the optimal dose of metformin could not be provided because the individual dosage data was not available from the NHIS database. The last limitation is the concern that there might be unmeasured confounding factors due to the retrospective design of the study, despite examining a large population. Information on other tumor-related parameters besides tumor stage, such as tumor differentiation, the presence of lymphovascular invasion, or the status of microsatellite instability, was unavailable.

Conclusion
==========

Metformin use was associated with the overall survival and cancer-specific survival in diabetic patients with nonmetastatic rectal cancer treated by a curative resection. These results could provide evidence for conducting future prospective randomized controlled trials.
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![Flowchart: study population. ICD-10, International Classification of Disease, 10th revision; SEER, Surveillance Epidemiology and End Result.](crt-2016-128f1){#f1-crt-2016-128}

![Survival curves comparing metformin and nonmetformin use in rectal cancer patients. (A) Overall survival. (B) Rectal cancer-specific survival. RMST, restricted mean survival time.](crt-2016-128f2){#f2-crt-2016-128}

![Survival curves comparing MPR levels for metformin in patients with rectal cancer. (A) Overall survival. (B) Rectal cancer-specific survival. MPR, medication possession ratio; RMST, restricted mean survival time.](crt-2016-128f3){#f3-crt-2016-128}

###### 

Baseline characteristics of the rectal cancer patients with diabetes mellitus

  Characteristic                                               Metformin group (n=3,694)   Nonmetformin group (n=809)   p-value
  ------------------------------------------------------------ --------------------------- ---------------------------- ----------
  **Sex**                                                                                                               
   Male                                                        2,397 (64.9)                520 (64.3)                   0.741
   Female                                                      1,297 (35.1)                289 (35.7)                   
  **Age, median (interquartile range, yr)**                    65 (58-71)                  67 (60-73)                   \< 0.001
  **SEER stage**                                                                                                        
   Localized                                                   1,393 (37.7)                304 (37.6)                   0.980
   Regional                                                    2,016 (54.6)                444 (54.9)                   
   Unknown                                                     285 (7.7)                   61 (7.5)                     
  **Radiotherapy**                                             1,322 (35.8)                273 (33.7)                   0.271
   Before surgery                                              781 (21.1)                  153 (18.9)                   0.157
   After surgery                                               541 (14.6)                  120 (14.8)                   0.891
  **Preoperative chemotherapy**                                697 (18.9)                  137 (16.9)                   0.200
  **Adjuvant chemotherapy**                                    1123 (30.4)                 216 (26.7)                   0.037
  **Charlson comorbidity index score (interquartile range)**   5 (4-7)                     6 (4-7)                      
   0-3                                                         692 (18.7)                  155 (19.2)                   0.140
   4-6                                                         1,778 (48.1)                356 (44)                     
   7-9                                                         976 (26.4)                  242 (29.9)                   
   ≥ 10                                                        248 (6.7)                   56 (6.9)                     

Values are presented as number (%) unless otherwise indicated. SEER, Surveillance Epidemiology and End Result.

###### 

Mortality risk based on metformin use in patients with rectal cancer

  Outcome                 Incidence    Unadjusted   Adjusted^[a)](#tfn1-crt-2016-128){ref-type="table-fn"}^                                    
  ----------------------- ------------ ------------ --------------------------------------------------------- ---------- --------------------- ----------
  Overall mortality       541 (14.6)   196 (24.2)   0.596 (0.506-0.702)                                       \< 0.001   0.653 (0.554-0.770)   \< 0.001
  RC-specific mortality   363 (9.8)    126 (15.6)   0.621 (0.507-0.760)                                       \< 0.001   0.662 (0.540-0.812)   \< 0.001

Values are presented as number (%). HR, hazard ratio; CI, confidence interval; RC, rectal cancer; SEER, Surveillance Epidemiology and End Result.

Adjusted: sex, age, SEER stage, Charlson's comorbidity index score, preoperative chemotherapy, adjuvant chemotherapy.

###### 

Mortality risk based on the MPR levels in the metformin group

  Outcome                 Incidence    Unadjusted   Adjusted^[a)](#tfn2-crt-2016-128){ref-type="table-fn"}^                                    
  ----------------------- ------------ ------------ --------------------------------------------------------- ---------- --------------------- ----------
  Overall mortality       179 (10.5)   362 (18.2)   0.606 (0.506-0.724)                                       \< 0.001   0.631 (0.527-0.755)   \< 0.001
  RC-specific mortality   116 (6.8)    247 (12.4)   0.573 (0.459-0.714)                                       \< 0.001   0.598 (0.479-0.746)   \< 0.001

Values are presented as number (%). MPR, medication possession ratio; HR, hazard ratio; CI, confidence interval; RC, rectal cancer; SEER, Surveillance Epidemiology and End Result.

Adjusted: sex, age, SEER stage, Charlson's comorbidity index score, preoperative chemotherapy, adjuvant chemotherapy.
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